hyaluronic acid 是一种治疗药物，由Johnson & Johnson Services, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intraarticular Injection。
| 商品名 | BioHy, Euflexxa, BioLon |
| 公司 | Johnson & Johnson Services, Inc. |
| 给药途径 | Injectable (Others), Intraarticular Injection |
| 状态 | Approved |
hyaluronic acid 针对 4 个适应症，涉及 3 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Eye disorders | Glaucoma | ✓ Approved |
| Musculoskeletal and connective tissue disorders | Osteoarthritis | ✓ Approved |
| Surgical and medical procedures | Adjuvant therapy | ✓ Approved |
| Eye disorders | Dry eye | Phase II |
Li Jingchao J, He Yao Y, Sun Wenjie W, Luo Yu Y et al.
Tratnjek Larisa L, Simic Laura L, Jerman Urška Dragin UD, Sušanj Ivan I et al.
A new nasal formulation combining xylometazoline, a well-established nasal decongestant, and hyaluronic acid (HA) at a 3 mg/ml concentration and low-molecular-weight has been developed as a topical product intended for use in viral acute rhinosinusitis, with the aim of relieving nasal congestion and supporting epithelial integrity. HA, a moisturizing component of respiratory secretions, has been shown to promote epithelial integrity, stimulate mucociliary clearance and support wound healing. As part of the drug development process, this study investigated the permeation and penetration properties of xylometazoline, and HA in the new formulation using a human nasal epithelium in vitro model. Results were compared to those of a xylometazoline mono-formulation and a well-established fixed-dose combination of xylometazoline and dexpanthenol. Morphological, ultrastructural and physiological analyses were performed to test nasal cells tolerability on prolonged drug exposure (6 h). HA in this new nasal formulation seems to be a component that exerts its effect mainly on the mucosal surface, which is the favoured site of action for topical products. HA was not detected in the basolateral compartment, consistent with retention at the mucosal surface. The results of our preclinical study do not indicate that the safety profile of xylometazoline would be altered by the addition of HA (or dexpanthenol). The barrier integrity of the in vitro human nasal epithelium was preserved across all tested formulations Nanoparticle endocytosis was absent. These findings, obtained in a healthy in vitro nasal epithelial model, provide a valuable foundation for subsequent evaluation of this formulation in human clinical studies.
Guan Yimeng Y, Edny Gisella G, Chandra Janin J, Souza-Fonseca-Guimaraes Fernando F et al.
Tumor heterogeneity in cutaneous melanoma (CM) is attributed to the functional and structural diversity of tumor cells, immune cells, and the tumor stroma, and determines patients' response to therapy. The tumor immune microenvironment (TIME) comprises a diverse array of cellular and non-cellular components. Cells include cancer-associated fibroblasts, T cells, NK cells, B cells, dendritic cells, myeloid-derived suppressor cells, and monocytes. Non-cellular components include cytokines, growth factors, and extracellular matrix (ECM). In this review, we specifically focus on the critical roles of ECM molecules, namely collagen, fibronectin, laminin, hyaluronic acid, galectin, and matrix metalloproteinase, in shaping the melanoma TIME. We explore ECM components by examining how their physical properties and biological functions regulate the interactions between cancer and immune cells, thereby impacting immunity in melanoma and underscoring their clinical significance.
Zhang Di D, Ma Shen Hong SH, Wang He Ling HL, Han Qiao Hua QH et al.
The aim of this study is to compare the clinical efficacy and safety of platelet-rich plasma (PRP) and hyaluronic acid in the treatment of hip osteoarthritis. Data were collected from the PubMed, Embase, Cochrane Library, and Web of Science databases. The outcomes selected included the Visual Analog Scale (VAS) score, the Harris Hip Score (HHS), the Western Ontario, and McMaster Universities Osteoarthritis Index (WOMAC) and its relevant subscores. A standardized mean difference (SMD) was used as the combined effect size, and a random-effects model was applied for analysis. The magnitude of the effect size was interpreted according to Jacob Cohen's criteria. A total of seven studies involving 465 patients were included. The meta-analysis results indicated that in terms of pain relief, the PRP group showed a statistically significant advantage in VAS scores at 6 months (SMD = -0.38 and p = 0.01). Subgroup analysis revealed that LP-PRP yielded significant improvement (SMD = -0.32 and p = 0.02), whereas LR-PRP did not (SMD = -0.46 and p = 0.18). Similarly, multiple injections (SMD = -0.43 and p = 0.02) demonstrated superiority compared to a single injection (SMD = -0.12 and p = 0.63).Regarding WOMAC-pain scores, the PRP group exhibited statistical differences at 6 months (SMD = -0.45 and p = 0.0006) and 12 months (SMD = -0.36 and p = 0.03). In terms of functional impairment, no significant differences were found in the HHS (SMD = 0.13 and p = 0.64) or WOMAC subscores (WOMAC-stiffness: SMD = 0.01 and p = 0.97 and WOMAC-function: SMD = -0.24 and p = 0.06) at any follow-up time point. However, the WOMAC total score indicated that the overall health status of patients in the PRP group was superior to that in the HA group after treatment (SMD = -0.42 and p = 0.009). The findings of this study indicate that compared with HA, PRP demonstrates a statistically significant advantage in alleviating pain (VAS and WOMAC-pain) and improving overall symptoms (WOMAC total score) in patients with hip osteoarthritis (HOA) although the effect size was found to be moderate. However, regarding the improvement of joint function (HHS and WOMAC-function), no significant differences were observed between the two groups. In summary, while PRP presents a statistical benefit over HA in the treatment of HOA, the effect size is limited; therefore, further high-quality studies are warranted to definitively confirm its clinical superiority.
Koppert Erik E, Zamin Roya Zarmehr RZ, Lee Suyeon S, Yi Kyu-Ho KH
Enlarged facial pores are a common aesthetic concern associated with aging and reduced dermal support. Hybrid Cooperative Complex (HCC), a stabilized hyaluronic acid formulation, has been proposed to improve skin quality through bioremodeling. This prospective observational pilot study evaluated changes in facial pore size after treatment with Hybrid Cooperative Complex (HCC) using standardized photography, clinical assessment, and validated rating scales. Ten healthy adult participants received two treatment sessions according to the Bio Aesthetic Points protocol, and outcomes were assessed at baseline and on Days 30, 60, 120, and 180. Visible improvement in facial pore size and skin texture was observed after treatment. Peak pore refinement was noted at Day 120 in most participants, while partial regression was observed in many cases by Day 180, although skin quality remained improved compared with baseline. HCC may be associated with visible improvement in facial pore size and skin quality in this pilot cohort. Changes in pore morphology may represent a practical clinical marker for estimating maintenance treatment timing, although larger controlled studies are needed.
Khouja Bashayer A BA, Zeng Hui H, Fay Megan L ML, Salazar Joelle K JK et al.
Peeled hard-cooked eggs (HCEs) are ready-to-eat foods susceptible to Listeria monocytogenes contamination during post-processing. A 2019 multistate listeriosis outbreak linked to HCEs treated with 0.3% citric acid highlighted the need for effective antimicrobial treatment. This study evaluated the efficacy of organic acid treatments (0.3% and 2% citric, and 2% acetic, lactic, and malic acids) at 5°C and 25°C against low-level contamination (1 log CFU/HCE) on HCEs during 28-day refrigerated storage (5°C). Two contamination scenarios were assessed: inoculation prior to acid treatment (simulating processing contamination) and inoculation after acid treatment (simulating post-treatment cross-contamination). For pre-treatment contamination, 2% acetic acid at 5°C achieved complete elimination of detectable L. monocytogenes by 3 d, while 2% malic acid demonstrated 0-1/9 positive samples from 7 to 28 days. In contrast, 0.3% citric acid and 2% lactic acid were least effective, maintaining ≥3/9 positive samples throughout storage. For post-treatment contamination, only 2% citric acid achieved elimination of detectable L. monocytogenes (by 14 days at 5°C and 7 days at 25°C). The pH of HCE components decreased significantly during treatment with the 2% organic acids, with 2% citric acid achieving the lowest albumen pH (3.13-3.69). These results demonstrate that organic acid effectiveness against L. monocytogenes on HCEs is dependent on acid type, concentration, and whether the contamination occurs pre- or post-processing. Data from this study can be used to better understand the survival of L. monocytogenes on HCEs treated with organic acids to ensure the safety of this food product.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →